Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease

(2018) Elizabeth F. Redente et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

(2018) Carlo Vancheri et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease–Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis

(2018) Jonathan H. Chung et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Safety of Nintedanib Added to Pirfenidone Treatment for Idiopathic Pulmonary Fibrosis

(2018) Kevin R. Flaherty et al.   EUROPEAN RESPIRATORY JOURNAL

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis

(2018) Sergio Harari et al.   RESPIRATION

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

(2018) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?

(2018) Bridget F. Collins et al.   RESPIRATORY MEDICINE

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

(2018) Bruno Crestani et al.   Lancet Respiratory Medicine

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

(2018) Pierre-Antoine Juge et al.   NEW ENGLAND JOURNAL OF MEDICINE

Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis

(2017) Joseph Jacob et al.   EUROPEAN RADIOLOGY

Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years

(2017) Ganesh Raghu   EUROPEAN RESPIRATORY JOURNAL

Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis

(2017) Harold R. Collard et al.   EUROPEAN RESPIRATORY JOURNAL

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)

(2017) Ulrich Costabel et al.   RESPIRATION

High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival

(2017) Zulma X. Yunt et al.   RESPIRATORY MEDICINE

Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices

(2017) Joseph Jacob et al.   RESPIRATORY MEDICINE

Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients

(2017) Kais Ahmad et al.   RESPIRATORY MEDICINE

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

(2017) Jürgen Behr et al.   BMC Pulmonary Medicine

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis

(2017) Nicole S. Goh et al.   Arthritis & Rheumatology

The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study

(2017) Brett Ley et al.   Lancet Respiratory Medicine

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function

(2016) Carlo Albera et al.   EUROPEAN RESPIRATORY JOURNAL

Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive

(2016) Chad A. Newton et al.   EUROPEAN RESPIRATORY JOURNAL

Characterisation of patients with interstitial pneumonia with autoimmune features

(2016) Justin M. Oldham et al.   EUROPEAN RESPIRATORY JOURNAL

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

(2016) D. Khanna et al.   JOURNAL OF RHEUMATOLOGY

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

(2016) Wim A. Wuyts et al.   LUNG

Unclassifiable interstitial lung diseases: Clinical characteristics and survival

(2016) Charlotte Hyldgaard et al.   RESPIROLOGY

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

(2016) Martin Kolb et al.   THORAX

Management of interstitial lung disease associated with connective tissue disease

(2016) Stephen C Mathai et al.   BMJ-British Medical Journal

Management of interstitial lung disease associated with connective tissue disease

(2016) Stephen C Mathai et al.   BMJ-British Medical Journal

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis

(2016) Ting Li et al.   Scientific Reports

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

(2015) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials

(2015) Harold R. Collard et al.   EUROPEAN RESPIRATORY JOURNAL

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

(2015) Aryeh Fischer et al.   EUROPEAN RESPIRATORY JOURNAL

Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib

(2015) Banu A. Karimi-Shah et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

(2015) Satoshi Ikeda et al.   BMC Pulmonary Medicine

Cord Blood-Derived Cytokine-Induced Killer Cellular Therapy Plus Radiation Therapy for Esophageal Cancer

(2015) Liming Wang et al.   MEDICINE

All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials

(2014) Talmadge E. King et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses

(2014) Neil Ahluwalia et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Prevalence and prognosis of unclassifiable interstitial lung disease

(2014) L. Troy et al.   EUROPEAN RESPIRATORY JOURNAL

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

(2014) Takashi Ogura et al.   EUROPEAN RESPIRATORY JOURNAL

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

(2014) Keith C. Meyer et al.   EUROPEAN RESPIRATORY JOURNAL

Transforming growth factor β—at the centre of systemic sclerosis

(2014) Robert Lafyatis   Nature Reviews Rheumatology

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review: Interstitial Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct?

(2014) Erica L. Herzog et al.   Arthritis & Rheumatology

Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial

(2014) Ganesh Raghu et al.   Lancet Respiratory Medicine

An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

(2013) William D. Travis et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease

(2013) Rekha Vij et al.   CHEST

Efficacy of Pirfenidone in Patients with Advanced-stage Idiopathic Pulmonary Fibrosis

(2013) Susumu Sakamoto et al.   INTERNAL MEDICINE

Usual interstitial pneumonia-patternfibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology

(2013) Maxwell Smith et al.   JOURNAL OF CLINICAL PATHOLOGY

A new classification system for chronic lung allograft dysfunction

(2013) Geert M. Verleden et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Rheumatoid Arthritis–associated Interstitial Lung Disease: Radiologic Identification of Usual Interstitial Pneumonia Pattern

(2013) Deborah Assayag et al.   RADIOLOGY

Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment

(2013) Harpreet K Lota et al.   THORAX

Association of Interferon- and Transforming Growth Factor β-Regulated Genes and Macrophage Activation With Systemic Sclerosis-Related Progressive Lung Fibrosis

(2013) Romy B. Christmann et al.   Arthritis & Rheumatology

Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study

(2013) Ferran Morell et al.   Lancet Respiratory Medicine

Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials

(2012) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Prevalence and prognosis of unclassifiable interstitial lung disease

(2012) Christopher J. Ryerson et al.   EUROPEAN RESPIRATORY JOURNAL

Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary Fibrosis

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear

(2012) Athol U Wells   THORAX

Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis

(2011) Roland M. du Bois et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide

(2011) Hyun J. Kim et al.   EUROPEAN RADIOLOGY

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

(2011) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study

(2011) N. Arulkumaran et al.   RHEUMATOLOGY

Pathologic Patterns and Survival in Chronic Hypersensitivity Pneumonitis

(2009) Andrew Churg et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Rheumatoid Arthritis-Associated Interstitial Lung Disease

(2009) Eunice J. Kim et al.   CHEST

Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis

(2009) G. E. Tzelepis et al.   EUROPEAN RESPIRATORY JOURNAL

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

(2009) C. J. Zappala et al.   EUROPEAN RESPIRATORY JOURNAL

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease

(2009) E. J. Kim et al.   EUROPEAN RESPIRATORY JOURNAL

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

(2009) Talmadge E King et al.   LANCET

Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts

(2007) Seiko Nakayama et al.   LIFE SCIENCES